Novartis’ Kymriah shows ‘strong efficacy’, ‘durable response’ in new analysis
Novartis has released longer-term analyses of data from the ELIANA and JULIET trials showing that its CAR-T cell therapy Kymriah demonstrated “strong efficacy” and “durable responses” in certain blood cancer patients.
Read More
